- Home
- CGEM vs YALA Comparison
CGEM vs YALA Comparison
Compare CGEM & YALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | YALA |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United Arab Emirates |
| Employees | N/A | 849 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.4M | 841.1M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGEM | YALA |
|---|---|---|
| Price | $11.44 | $5.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $34.60 | $7.28 |
| AVG Volume (30 Days) | ★ 720.7K | 350.9K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | ★ 5.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.00 |
| Revenue Next Year | $300.03 | $12.03 |
| P/E Ratio | ★ N/A | $8.76 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.25 | $5.01 |
| 52 Week High | $23.19 | $7.67 |
Technical Indicators
Market Signals| Indicator | CGEM | YALA |
|---|---|---|
| Relative Strength Index (RSI) | 33.19 | 54.07 |
| Support Level | N/A | $5.22 |
| Resistance Level | $16.31 | $5.66 |
| Average True Range (ATR) | 1.19 | 0.11 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 12.69 | 69.39 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.